Latest News

First anticoagulant approved for preventing VTE recurrence in children




(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month or older, the U.S. Food and Drug Administration announced.

Source link




Related posts

Three-drug combo improves lung function in most common genetic form of cystic fibrosis

Newsemia

Medical News Today: Can a heart treatment lower depression and anxiety?

Newsemia

The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy